Effect of Sinopodophyllum Hexundrum Combined with Imatinib on Proliferation of K562 Cells in Chronic Myeloid Leukemia

Cai Jia¹, Zhou Fangzhu¹, Ren Qingbasong², Wang Dui², Huang Zhenglan¹, Wang Xin³*, Feng Wenli¹*

(¹College of Laboratory Medicine, Key Laboratory of Laboratory Medical Diagnostics by the Ministry of Education, Chongqing Medical University, Chongqing 400016, China; ²Tibet Changdu Tibetan Hospital, Tibet 854000, China; ³Hematology, The Hospital Group of the First Affiliated Hospital Of CQMU, Chongqing 400016, China)

Abstract:

To investigate the effects of Sinopodophyllum hexundrum combined with imatinib (IM) on proliferation of chronic myeloid leukemia K562 cells. K562 cells were treated with Sinopodophyllum hexundrum Imatinib, and joint processing, the effect of growth inhibition of K562 cells was detected by CCK8 and cell cloning assay method. Cell cycles were measured by flow cytometry analysis (FCM). Indirect immunofluorescence and Western blotting were used to detect the effects of the fusion BCR-ABL protein and its downstream JAK/STAT signaling pathway-related molecules. The results showed that compared with the use of Sinopodophyllum hexundrum or IM alone, the Sinopodophyllum hexundrum combined with IM can inhibit the growth and clonal formation of K562 cells more effectively, and block the K562 cell cycle in the G2/M phase. The expression and phosphorylation levels of BCR-ABL fusion protein and its downstream STAT5 signaling pathway were significantly reduced. In conclusion, Sinopodophyllum hexundrum and Imatinib has a synergistic effect and can inhibit the proliferation of K562 cells in chronic myeloid leukemia, which may be related to cell cycle arrest and inhibition of BCR-ABL-JAK-STAT5 signaling pathway.

CSTR: 32200.14.cjcb.2019.06.0011